Waters (NYSE:WAT – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 12.750-13.050 for the period, compared to the consensus estimate of 12.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Waters also updated its Q2 2025 guidance to 2.880-2.980 EPS.
Analyst Ratings Changes
A number of equities analysts recently weighed in on WAT shares. Baird R W raised shares of Waters from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 26th. Sanford C. Bernstein set a $400.00 price objective on Waters and gave the stock an “outperform” rating in a research report on Wednesday, April 16th. Barclays dropped their target price on Waters from $400.00 to $350.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Wells Fargo & Company upped their price target on Waters from $415.00 to $420.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Robert W. Baird lowered their price objective on shares of Waters from $407.00 to $355.00 and set an “outperform” rating on the stock in a report on Tuesday, April 22nd. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $392.13.
View Our Latest Stock Analysis on Waters
Waters Trading Down 0.6 %
Waters (NYSE:WAT – Get Free Report) last issued its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 EPS for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. Analysts expect that Waters will post 12.86 earnings per share for the current year.
Institutional Trading of Waters
An institutional investor recently raised its position in Waters stock. Brighton Jones LLC grew its stake in shares of Waters Co. (NYSE:WAT – Free Report) by 112.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,269 shares of the medical instruments supplier’s stock after acquiring an additional 673 shares during the period. Brighton Jones LLC’s holdings in Waters were worth $471,000 at the end of the most recent quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.
Waters Company Profile
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Recommended Stories
- Five stocks we like better than Waters
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Chevron’s Fundamentals Shine Through Market Turmoil
- Breakout Stocks: What They Are and How to Identify Them
- Qualcomm: Analyst Opinions Split, But Upside Potential Remains
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Monster Beverage Stock: Short Report Risks vs Upside Potential
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.